A. Mamedov

发表

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Alexandre Mamedov, Liying Zhang, L. Klotz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Danny Vesprini, Alexandre Mamedov, Liying Zhang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts

Lurdes Y. T. Inoue, M. Cooperberg, P. Carroll, 2018, Annals of Internal Medicine.

Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.

A. Kiss, P. Cheung, C. Danjoux, 2012, International journal of radiation oncology, biology, physics.

Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion‐dependent patients with myelodysplastic syndromes

R. Wells, J. Callum, R. Buckstein, 2017, Vox sanguinis.

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry

B. Leber, R. Wells, K. Yee, 2017, Annals of Hematology.

Initial transfusion intensity predicts survival in myelodysplastic syndrome

R. Wells, A. Prica, J. Callum, 2014, Leukemia & lymphoma.

The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes

Y. Liu, B. Leber, C. Earle, 2022, Annals of Hematology.

Improving clinical trial accrual through a novel feedback approach: Lessons learned from a single disease site group.

L. D'alimonte, A. Deabreu, A. Loblaw, 2015, Practical radiation oncology.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.

Hans T. Chung, Liying Zhang, P. Cheung, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.

Hans T. Chung, Liying Zhang, P. Cheung, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Liying Zhang, L. Klotz, D. Vesprini, 2016, The Journal of urology.

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Christopher P. Filson, D. Nieboer, E. Steyerberg, 2021, European urology open science.

Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging.

P. Cheung, G. Morton, D. Loblaw, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.

Liying Zhang, L. Klotz, A. F. Ghiam, 2020, The Journal of urology.

Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.

B. McCurdy, P. Cheung, S. Roy, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Predictive parameters of symptomatic haematochezia following 5-fraction gantry-based SABR in prostate cancer.

Hans T. Chung, Liying Zhang, P. Cheung, 2016 .

Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer.

A. Kiss, C. Danjoux, R. Choo, 2011, Nutrition research.

Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Liying Zhang, L. Klotz, D. Vesprini, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial.

Hans T. Chung, Liying Zhang, P. Cheung, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

R. Kerbel, R. Wells, Y. Shaked, 2014, Leukemia research.

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

K. Yee, P. Spin, R. Buckstein, 2022, Leukemia & lymphoma.

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

J. Maciejewski, B. Jha, M. Sekeres, 2022, iScience.

Journal Pre-proof A machine learning model of response to hypomethylating agents in myelodysplastic syndromes in

J. Maciejewski, B. Jha, M. Sekeres, 2022 .

Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study

B. Leber, K. Yee, R. Buckstein, 2021, British journal of haematology.

RBC-Enhance: A Randomized Pilot Feasibility Trial of Red Cell Transfusion Thresholds in Myelodysplastic Syndromes

B. Leber, K. Yee, A. Prica, 2020, Blood.

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

B. Leber, R. Wells, K. Yee, 2019, Blood.

Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.

Hans T. Chung, Liying Zhang, B. McCurdy, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

P. Cheung, L. D'alimonte, W. Chu, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Comparative Study of Quality of Life in Patients with Localized Prostate Cancer Treated in a Single Institution: Stereotactic Radiotherapy or External Beam + High-Dose-Rate Brachytherapy Boost

Hans T. Chung, Liying Zhang, P. Cheung, 2014 .

Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).

Hans T. Chung, Liying Zhang, B. McCurdy, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comparison of Biochemical and Toxicity Outcomes From a Contemporaneous Cohort Study of Low-Risk Prostate Cancer Treated With Different Radiation Techniques

Hans T. Chung, P. Cheung, L. D'alimonte, 2013 .

Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.

R. Wells, S. Alibhai, J. Callum, 2009 .

Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.

Liying Zhang, L. Klotz, D. Vesprini, 2010, The Journal of urology.

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

D. Nieboer, B. Trock, P. Dasgupta, 2022, European urology open science.

B. Leber, R. Wells, K. Yee, 2014 .

CLINICAL RESULTS OF LONG TERM FOLLOW-UP OF A LARGE ACTIVE SURVEILLANCE COHORT

L. Klotz, A. Loblaw, R. Nam, 2009 .

Hans T. Chung, Liying Zhang, P. Cheung, 2011, International journal of radiation oncology, biology, physics.

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

J. Witte, M. Cooperberg, P. Carroll, 2021, medRxiv.

Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.

Liying Zhang, M. Kattan, L. Klotz, 2015, The Journal of urology.

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis

B. Leber, R. Wells, K. Yee, 2017, British journal of haematology.

The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.

R. Wells, J. Callum, Yulia Lin, 2019, Leukemia research.

Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.

Liying Zhang, B. McCurdy, P. Cheung, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - results from the 2SMART Phase 2 trial.

Liying Zhang, P. Cheung, M. McGuffin, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.

P. Cheung, L. D'alimonte, D. Loblaw, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

B. Leber, K. Rockwood, R. Wells, 2016, British journal of haematology.

Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I/II study.

P. Cheung, A. Gladwish, G. Morton, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

Liying Zhang, P. Cheung, L. D'alimonte, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed.

Liying Zhang, P. Cheung, A. Gladwish, 2019, Practical radiation oncology.

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring

B. Leber, K. Rockwood, R. Wells, 2019, Leukemia.

Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes

Y. Liu, B. Leber, C. Earle, 2023, JCO oncology practice.

Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?

Liying Zhang, É. Vigneault, P. Cheung, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

Liying Zhang, P. Cheung, C. Danjoux, 2010, International journal of radiation oncology, biology, physics.

Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

Liying Zhang, P. Cheung, D. Vesprini, 2016, International journal of radiation oncology, biology, physics.

Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.

Liying Zhang, P. Cheung, A. Deabreu, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.

Liying Zhang, B. McCurdy, P. Cheung, 2015 .

Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients

Catherine Han Lin, M. Kattan, D. Nieboer, 2021, Translational Andrology and Urology.

A first step towards a global nomogram to predict disease progression for men on active surveillance

Catherine Han Lin, M. Kattan, D. Nieboer, 2020, Translational andrology and urology.

The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes

Y. Liu, B. Leber, C. Earle, 2021, Annals of Hematology.

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials

Liying Zhang, P. Cheung, A. Deabreu, 2016, Front. Oncol..

A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.

Liying Zhang, P. Cheung, G. Morton, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.

Liying Zhang, P. Cheung, E. Szumacher, 2021, Radiotherapy and Oncology.

Clinical Investigation : Genitourinary Cancer Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer

A. Kiss, P. Cheung, C. Danjoux, 2012 .

Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.

Liying Zhang, P. Cheung, A. Deabreu, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?

Liying Zhang, P. Cheung, M. McGuffin, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

PATRIOT Trial: Randomized Phase 2 Study of Prostate Stereotactic Body Radiation Therapy Comparing 11 Versus 29 Days Overall Treatment Time

B. McCurdy, P. Cheung, D. Vesprini, 2015 .

Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.

Liying Zhang, P. Cheung, C. Danjoux, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial.

Liying Zhang, P. Cheung, W. Chu, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.

Liying Zhang, B. McCurdy, P. Cheung, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database

Catherine Han Lin, D. Nieboer, E. Steyerberg, 2022, The Prostate.

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.

Liying Zhang, P. Cheung, M. McGuffin, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Liying Zhang, L. Klotz, A. Loblaw, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1460 OVERALL SURVIVAL (OS) AND PROSTATE CANCER-SPECIFIC MORTALITY (PCSM) AMONG CONTEMPORARY MEN WITH SCREEN-DETECTED, LOCALIZED PROSTATE CANCER MANAGED BY ACTIVE SURVEILLANCE (AS) VERSUS DEFINITIVE LOCAL THERAPY

M. Kattan, A. Kibel, J. Ciezki, 2011 .

Initial transfusion intensity predicts survival in myelodysplastic syndrome

R. Wells, A. Prica, J. Callum, 2014, Leukemia and Lymphoma.

B. Leber, K. Rockwood, R. Wells, 2016, British journal of haematology.

Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

B. Leber, R. Wells, K. Yee, 2015 .

Liying Zhang, P. Cheung, G. Morton, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.

L. Klotz, D. Vesprini, D. Loblaw, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liying Zhang, P. Cheung, C. Danjoux, 2011, International journal of radiation oncology, biology, physics.

Adult Urology Oncology: Prostate/Testis/Penis/Urethra Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer

Liying Zhang, L. Klotz, A. F. Ghiam, 2022 .